Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies

Cristina Varas-Lorenzo1*, Nuria Riera-Guardia1, Brian Calingaert2, Jordi Castellsague1, Francesco Salvo3, Federica Nicotra4, Miriam Sturkenboom5 and Susana Perez-Gutthann1

1RTI Health Solutions, Barcelona, Spain
2RTI Health Solutions, Research Triangle Park, NC, United States
3Université Victor Segalen, Bordeaux, France
4Department of Statistics, Biostatistics and Epidemiology Unit, University of Milano-Bicocca, Milan, Italy
5Erasmus University Medical Center, Rotterdam, Netherlands

ABSTRACT
Objective To conduct a systematic review of observational studies on the risk of acute myocardial infarction (AMI) with use of individual nonsteroidal anti-inflammatory drugs (NSAIDs).

Methods A search of Medline (PubMed) for observational studies published from 1990 to 2011 identified 3829 articles; 31 reported relative risk (RR) of AMI with use of individual NSAIDs versus nonuse of NSAIDs. Information abstracted in a standardized form from 25 publications was used for the meta-analysis on 18 independent study populations.

Results Random-effects RR (95% confidence interval (CI)) was lowest for naproxen 1.06 (0.94–1.20), followed by celecoxib 1.12 (1.00–1.24), ibuprofen 1.14 (0.98–1.31), meloxicam 1.25 (1.04–1.49), rofecoxib 1.34 (1.22–1.48), diclofenac 1.38 (1.26–1.52), indomethacin 1.40 (1.21–1.62), etodolac 1.55 (1.16–2.06), and etoricoxib 1.97 (1.35–2.89). Heterogeneity between studies was present. For new users, RRs (95% CIs) were for naproxen, 0.85 (0.73–1.00); ibuprofen, 1.20 (0.97–1.48); celecoxib, 1.23 (1.00–1.52); diclofenac, 1.41 (1.08–1.86); and rofecoxib, 1.43 (1.21–1.66).

Except for naproxen, higher risk was generally associated with higher doses, as defined in each study, overall and in patients with prior coronary heart disease. Low and high doses of diclofenac and rofecoxib were associated with high risk of AMI, with dose–response relationship for rofecoxib. In patients with prior coronary heart disease, except for naproxen, duration of use ≤3 months was associated with an increased risk of AMI.

Conclusions Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or in persons with diagnosed coronary heart disease. For diclofenac and rofecoxib, the risk was increased at low and high doses.

Copyright © 2013 John Wiley & Sons, Ltd.

INTRODUCTION

The cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) is still under scrutiny after the introduction of selective cyclooxygenase-2 (COX-2) inhibitors.1–3 The United States (US) Food and Drug Administration and the European Medicines Agency reviewed the safety of selective COX-2 inhibitors, resulting in their contraindication in patients with ischemic heart disease, stroke, or peripheral arterial disease.

Syntheses of published interventional and observational studies conclude that both selective and nonselective COX-2 inhibitors increase the risk of acute myocardial infarction (AMI), and this risk varies across individual NSAIDs.4–7 Cardiovascular toxicity associated with selective COX-2 and some traditional
NSAIDs is mediated through a common mechanism involving the inhibition of COX-2-dependent prosta- cyclin. Naproxen, at high doses in some individuals, is the only nonaspirin NSAID that lacks functional COX-2 selectivity in platelets.8,9

Within the Safety of NSAID (SOS) project, a research and development project funded by the Directorate General of Research and Innovation of the European Commission under the Seventh Framework Programme, we performed a quantitative systematic literature review of observational studies assessing the risk of cardiovascular events associated with the use of NSAIDs. (http://www.sos-nsaids-project.org).

METHODS

Data sources, data extraction, and quality assessment

We performed a systematic literature search on cardiovascular events in the Medline database (PubMed) using free-text search terms and Medical Subject Headings for myocardial infarction, acute coronary syndrome, sudden cardiac death, stroke, heart failure, left ventricular dysfunction, and nonsteroidal anti-inflammatory agents (see online material). We examined references of articles for additional sources.

Eligible studies for review were observational cohort or case–control studies published in peer-reviewed journals from January 1, 1990, through May 4, 2011. Our search period started in 1990 because the first epidemiology study on the risk of AMI and NSAIDs was published in 2000.4,6

We used the Newcastle-Ottawa Scale10 to evaluate the selection and comparability of study groups and ascertainment of the exposure in case–control studies or of the outcome in cohort studies. Two investigators (NR and CV) evaluated the quality and methodological limitations of each study for the assessment of potential biases, and discordances were solved by consensus.

Data synthesis and analysis

Using a standardized form, we extracted the odds ratio (OR) or relative risk (RR) for each individual NSAID estimated in each study from the model that was adjusted for the largest number of factors. The main analysis was conducted on all subjects exposed to individual NSAIDs and all types of AMI events. A dose–response analysis used the reported low-medium and high-dose estimates from each study. Data were limited for the evaluation of the effect of duration for individual NSAIDs. We performed several sensitivity analyses.

We estimated pooled RRs and 95% CI for the effect of each NSAID with at least three point estimates from independent studies, using the inverse variance weighting method.11 Fixed and random effects were estimated, but Forest plots were based on the random-effects models. Heterogeneity between studies was assessed by Cochran’s $\chi^2$ test of homogeneity. Tau$^2$ was used to quantify the between-study variance for random-effects models. The Higgins $I^2$ statistic was used to describe the percentage of between-study variability in effect estimates attributable to true heterogeneity rather than chance. The $\chi^2$ test was used to test for homogeneity between subgroups. Publication bias was examined by review of funnel plots. The analysis was conducted using Review Manager software (version 5.0.22, The Nordic Cochrane Centre, Copenhagen).

RESULTS

Study selection and characteristics of included studies

For inclusion in the meta-analysis, studies were required to provide measures of association comparing the risk of AMI between users of individual NSAIDs and nonusers or remote NSAID users. The broad search identified 3829 articles; after initial exclusions, the full text of 85 articles was reviewed (Figure 1). A total of 42 articles met the inclusion criteria for study design, outcome of interest, and study medications; of them, 11 were excluded because they used another reference category than non use or remote use of NSAID, resulting in 31 for inclusion (see Table 1). Because 20 out of the 31 articles selected for inclusion reported on the same source populations, for each data source, we included the most recent study results for the main analysis ($n = 18$).12–29 additional publications ($n = 7$) provided data for subgroup analyses,30–36 and the other six did not provide additional information for the analysis (see online material).

Table 1 describes the 25 articles providing data for the main meta-analysis of AMI (from 18 independent studies) or subgroup analyses. The studies were cohort12–14,19,24,29,35,36 or nested case–control15,17,18,21–23,25–27,30–34 studies using automated health databases and involved a large number of study subjects. Three field case–control studies16,20,28 assessed exposure by interviewing patients and controls. The studied populations ranged from low-medium to high risk according to the prior MI or CHD history of participants (Table 1). Half of the studies described the aspirin use, ranging from less than 3% to about 30% of the studied population. The proportion of fatal events varied across studies. The definition of current use was mostly homogeneous, including use at index.
NSAID USE AND RISK OF MYOCARDIAL INFARCTION

Figure 1. Flow chart of identification and selection of studies. Note: the individual NSAIDs used as reference in each of the 11 excluded studies were the following: diclofenac (n = 2); ibuprofen or diclofenac (n = 1); meloxicam (n = 1); rofecoxib (n = 1); celecoxib (n = 2); acetaminophen (n = 1); aspirin (n = 1); non-naproxen NSAIDS (n = 1); non-selective NSAIDS (n = 1).

Table 1. Main characteristics of studies included in the meta-analysis

| Source population, study period                                      | Population, N, prior MI/CHD (%) | AMI ascertainment                                      | Current use         |
|---------------------------------------------------------------------|---------------------------------|--------------------------------------------------------|---------------------|
| **Cohort studies**                                                   |                                 |                                                        |                     |
| Denmark, 1997–2006                                                   | N: 83 675; MI: 100%             | Fatal/nonfatal recurrent                               | Five time periods   |
| Denmark, 1997–2005                                                   | N: 1 028 427; MI: 0%            | First-ever fatal/nonfatal                              | At index day        |
| Denmark, 1995–2006                                                   | N: 58 432; MI: 100%             | Recurrent fatal/nonfatal; included OOH CHD deaths      | At index date       |
| Medicare, US, 1999–2003                                              | N: 98 370; MI: 7%               | Fatal/nonfatal                                         | At index day        |
| US, Canada and UK, 1999–2004                                         | N: 48 566; CHD: 100%           | Fatal/nonfatal, included OOH CHD deaths                | At index day        |
| Veterans Administration, US, 2000–2002                               | N: 384 322; MI: 0.8–1.2%       | Fatal/nonfatal                                         | Last 180 days       |
| Medicaid, TN, US, 1999–2001                                          | N: 453 962; NR                  | Fatal/nonfatal, included OOH CHD deaths                | At index day        |
| Ontario, Canada, 1998–2001                                           | N: 166 964; MI: 5%              | Fatal/nonfatal                                         | At index day        |
| **Nested or population-based case-control studies**                  |                                 |                                                        |                     |
| Medicare, US, 1991–1995                                             | N: 22 125; MI: 0%               | First-ever fatal/nonfatal                              | Last 180 days       |
| Kaiser Permanente, US, 1999–2001                                      | N: 1 394 764; MI: <1%           | Fatal/nonfatal included OOH CHD deaths                 | At index day        |
| Saskatchewan, Canada, 1999–2001                                      | N: 364 658; CHD: 16.5%          | Fatal/nonfatal, included OOH CHD deaths                | Last 14 or 7 days   |
| Quebec, Canada, 1999–2002                                            | N: 125 000; MI: 0% (31)–6.2%   | Fatal/nonfatal                                         | Last 7 days         |
| Quebec, Canada, 1999–2002                                            | N: 113 927; MI: 0%              | First-ever fatal/nonfatal                              | At index day        |
| GPRD, UK, 2000–2004                                                  | N: 486 378; CHD: 18.2%         | Fatal/nonfatal, included OOH CHD deaths                | Last 14 or 7 days   |
| GPRD, UK, 1997–2000                                                  | N: 404 183; CHD: 17%           | Fatal/nonfatal, included OOH CHD deaths                | Last 30 days        |
| THIN, UK, 2000–2005                                                  | N: 716 395; NR                  | Fatal/nonfatal                                         | Last 7 days         |
| QUEResearch, UK, 2000–2004                                           | N: 95 567; MI: 0%               | First-ever fatal/nonfatal, included OOH CHD deaths     | Last 90 days        |
| **PHARMO, The Netherlands, 2001–2004**                               | N: 485 059; CVD: 2.4%           | Fatal/nonfatal                                         | At index day        |
| Finland, 2000–2003                                                   | N: 172 258; MI: 0%              | First-ever fatal/nonfatal                              | At index day        |
| Denmark, 2000–2003                                                   | N: 113 077; MI: 0%              | First-ever fatal/nonfatal                              | Last 30 days        |
| **Hospital field case-control studies**                              |                                 |                                                        |                     |
| Philadelphia, US, 1998–2002                                          | N: 8518; MI: 0%                 | First-ever fatal                                       | Last 7 days         |
| Newcastle Australia, 2003–2004                                       | N: 806; NR                      | Fatal/nonfatal ACS                                     | Last 7 days         |
| Spain, 2007                                                        | N: 5908; MI: 5%                 | Fatal/nonfatal ACS                                     | Last 7 days         |

Note: First-ever AMI denotes the occurrence of the first AMI during the study period among patients without prior history of diagnosed MI. Recurrent AMI denotes the recurrence of an AMI among patients identified at the time of the qualifying AMI. Otherwise, AMI denotes the first occurrence of an AMI during the follow-up period among patients with and without prior history of a diagnosed MI.

Copyright © 2013 John Wiley & Sons, Ltd.  
Pharmacoepidemiology and Drug Safety, 2013; 22: 559–570  
DOI: 10.1002/pds
date or during 7 or 30 days, or less, before the index date.

Quality of studies

All except six studies\(^{12-14,19,20,26}\) reported a good selection and definition of subjects (see online material). One study reported results from an exposed cohort of patients who were dispensed at least two successive NSAID prescriptions for at least 30 days and followed for only 1 year.\(^{19}\) Immortal time bias was therefore present in this study. Two of the field case–control studies might have misclassified the exposure;\(^{16,20}\) in one, exposure was ascertained differently in cases (up to 7 days after the index date) than in controls (up to 4 months after the index date), likely resulting in differential misclassification of exposure.\(^{16}\)

Meta-analysis results

The random-effects summary estimate (RR; 95% CI) of the risk of AMI was lowest for naproxen (1.06; 0.94–1.20), followed by celecoxib (1.12; 1.00–1.24) and ibuprofen (1.14; 0.98–1.31). Meloxicam (1.25; 1.04–1.49), rofecoxib (1.34; 1.22–1.48), diclofenac (1.38; 1.26–1.52), indomethacin (1.40; 1.21–1.62), etodolac (1.55; 1.16–2.06), and etoricoxib (1.97; 1.35–2.89) were associated with an increased risk of AMI (eFigure 1). Fixed models produced summary estimates of similar magnitude but with more precision than random-effect models. Because heterogeneity was present across studies, we present only estimates under the random-effects models. There were no differences in the subgroup analyses between pooled estimates according study design. Field case–control studies provided very heterogeneous results, and the pooled estimates had wider 95% confidence limits; two of these studies reported very low ORs.\(^{16,20}\)

Table 2 summarizes results of analyses for the most frequently used NSAIDs, overall (all types of AMI) and restricted to first-ever incident cases, new users, or high-risk populations with prior coronary heart disease. First-ever incident AMI denotes the first occurrence of an AMI during the follow-up among patients without prior history of MI. New users were defined in each study by excluding prevalent users from the study analysis or including only cohorts of new users in the study.

The pooled estimates (RR; 95% CI) for new users were estimated for naproxen (0.85; 0.73–1.00), ibuprofen (1.20; 0.97–1.48), diclofenac (1.41; 1.08–1.86), celecoxib (1.23; 1.00–1.52), and rofecoxib (1.43; 1.23–1.66) (Table 2). The summary estimates restricted to studies defining new current users as those who were exposed at the index date provided similar results (Table 2).

| AMI | Naproxen | Ibuprofen | Diclofenac | Celecoxib | Rofecoxib |
|-----|----------|-----------|------------|-----------|-----------|
| 1.06 | 1.14 | 1.38 | 1.12 | 1.34 |
| (0.94, 1.20) | (0.98, 1.31) | (1.26, 1.52) | (1.00, 1.24) | (1.22, 1.48) |
| Heterogeneity (P value) | <0.00001 | <0.00001 | 0.005 | <0.00001 | 0.0005 |
| First-Ever AMI | 1.00 | 1.18 | 1.38 | 1.10 | 1.41 |
| (0.79, 1.26) | (1.01, 1.38) | (1.20, 1.60) | (0.90, 1.36) | (1.25, 1.59) |
| Heterogeneity (P value) | <0.00001 | <0.00001 | 0.05 | <0.00001 | 0.002 |
| New users | 0.85 | 1.20 | 1.41 | 1.23 | 1.43 |
| (0.73, 1.00) | (0.97, 1.48) | (1.08, 1.86) | (1.00, 1.52) | (1.23, 1.66) |
| Heterogeneity (P value) | <0.00001 | <0.00001 | 0.01 | <0.00001 | 0.009 |
| New users, at index date | 0.82 | 1.15 | 1.71 | 1.06 | 1.33 |
| (0.71, 0.95) | (0.94, 1.40) | (1.38, 2.12) | (0.89, 1.57) | (1.11, 1.58) |
| Heterogeneity (P value) | <0.00001 | <0.00001 | 0.01 | <0.00001 | 0.009 |
| High-risk populations | 1.13 | 1.32 | 1.34 | 1.28 | 1.37 |
| (0.87, 1.46) | (1.14, 1.52) | (0.91, 1.98) | (0.99, 1.64) | (1.06, 1.79) |
| Heterogeneity (P value) | <0.00001 | <0.00001 | 0.01 | <0.00001 | 0.003 |

Note: Reference group, no or remote NSAID use. Studies included in each analysis: \(*AMI^{12-20}\) *First-ever AMI;\(^{16,18,21,23,25,27,30,33}\) *New users;\(^{13,14,17,19,21,22,24,27,29,31}\) *New users at index date;\(^{13,14,19,24,29,31}\) *High-risk populations (populations with prior diagnosed AMI or CHD).\(^{17,21,29,32,33,35}\)

AMI = acute myocardial infarction.

Note: First-ever AMI denotes the occurrence of the first event during the study period among patients without prior history of diagnosed MI. Otherwise, AMI denotes the first occurrence of an AMI during the follow-up period among patients with and without prior history of a diagnosed MI.

Copyright © 2013 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2013; 22: 559–570 DOI: 10.1002/pds
 Restricting the analysis to studies that included out-of-hospital (community) coronary heart disease deaths in the definition of AMI yielded the following pooled estimates: naproxen, 1.09; ibuprofen, 1.09; celecoxib, 1.09; diclofenac, 1.37; and rofecoxib, 1.26. Information was inadequate to provide a pooled analysis stratified by fatal and nonfatal cases.

Studies covering early periods after the introduction of COX-2 inhibitors (from 1999 to 2002) yielded, for celecoxib, significantly lower summary RR (95% CI) estimates (0.97; 0.82–1.14) than the studies that covered a more extended period, through 2005, (1.21; 1.06–1.51) (P = 0.03).

We did not find differences between the summary estimates from studies conducted in the US, Canada, or Europe (data not shown).

Dose effect. Overall, 11 studies reported the effect of individual NSAID dose on the risk of AMI. Most studies used similar cut-off values to define low-medium and high daily doses, except for naproxen, for which definitions varied widely across studies. Three studies defined doses using slightly higher cut-off values than the other studies for all NSAIDs except rofecoxib (see online material).

Forest plots for the risk of AMI by dose for naproxen, ibuprofen, celecoxib, diclofenac, and rofecoxib compared with nonusers are in Figure 2. Except for naproxen, a tendency to higher risk was generally associated with higher doses, as defined in each study. Low and high doses of diclofenac and rofecoxib were associated with higher risk of AMI, but dose–response relationship was present only for rofecoxib (Figure 2). Heterogeneity between studies was reduced in the dose analysis. Similar results were observed in a sensitivity analysis that included only studies using the same cut-off point to define high dose (data not shown).

Duration effect. Few studies reported on the effects of treatment duration on the risk of AMI. No consistent pattern was observed across studies. For diclofenac, one study reported the highest RR with long-term duration of use. For celecoxib, rofecoxib, and etoricoxib, the highest RR were observed with shortest durations. Definitions varied across studies and prevented pooling of the effect estimates (see online material), except in the subgroup analysis restricted to studies performed in high-risk population (see following section).

High-risk populations. Prior CHD history

Table 2 presents results from six studies evaluating the risk of AMI in high-risk populations by CHD history. The population was stratified by prior history of AMI or of CHD. One publication reported the results of three cohorts (US, Canada, and UK) identified immediately after AMI, unstable angina, or coronary revascularization procedure. One study presented the risk of recurrent AMI and death. The pooled RR (95% CI) were for naproxen (1.13; 0.87–1.46), ibuprofen (1.32; 1.14–1.52), celecoxib (1.28; 0.99–1.64), diclofenac (1.34; 0.91–1.98), and rofecoxib (1.37; 1.06–1.79). Three of these studies provided data on dose effect, and two on treatment duration including one study that presented information from three population-based cohorts. High doses were associated with a high risk of AMI for ibuprofen and celecoxib; for diclofenac and rofecoxib, both low and high doses were associated with a high risk of AMI (Figure 3).

Concomitant aspirin use

Five studies presented analysis results in patients using aspirin concomitantly with the most frequently used individual NSAIDs, but two studies presented results from the same source population. Pooled RRs (95% CI) for each individual NSAID with or without concomitant use of aspirin were for naproxen, 0.95 (0.61–1.47) and 1.22 (0.78–1.92); celecoxib, 0.90 (0.73–1.10) and 0.94 (0.58–1.55); and rofecoxib, 1.14 (0.93–1.41) and 1.38 (1.17–1.63). Based in fewer than three studies, for ibuprofen, 1.15 (0.88–1.50) and 1.02 (0.79–1.31); meloxicam, 1.02 (0.52–2.00) and 1.23 (0.52–2.94); and finally for diclofenac, 1.29 (1.02–1.63) versus 1.79 (1.51–2.11) (X² = 4.96; p = 0.03).

Assessment of potential publication bias—Funnel plots. The funnel plots generated by graphing RR against the standard error of the log of RR appear quite symmetric for all five of the individual NSAIDs (see online material). Relatively few small studies were identified, and all of them found null associations (except for celecoxib in one study). As expected, in a few cases, some of the smaller studies had more extreme RR; this does not necessarily suggest publication bias but instead could reflect that the smaller study was of lesser quality or was perhaps conducted among a
particularly high-risk population.\textsuperscript{37} These findings argue against the presence of publication bias.

\textbf{DISCUSSION}

This meta-analysis of approximately 100 000 AMI events from 18 independent study populations and 64 000 AMI events in the subgroup analyses supports variability in the risk of AMI associated with current use of the most frequently used NSAIDs in comparison with nonuse of NSAIDs. Except for naproxen, almost all NSAIDs most frequently used in clinical practice, if used at high doses or in populations with prior CHD, are associated with an increased risk of AMI. Rofecoxib and diclofenac used at either low or high doses are
associated with an elevated risk of AMI, but higher doses of rofecoxib are associated with higher risk of AMI than low doses.

Our results were consistent with those of previous meta-analyses. Meta-analyses of randomized clinical trials reported an increased risk of vascular events associated with selective COX-2 inhibitors, largely attributable to a two-fold increased risk of AMI. High-dose regimens of diclofenac and ibuprofen, but not naproxen, were associated with similar excess risk. The authors acknowledged that the quality of the reported safety data from these trials was suboptimal. Poor quality of reported safety data in clinical trials prevented pooling of results.

Estimated risks of AMI were of similar magnitude and trend to those estimated in prior meta-analyses of observational studies but provide further insights on dose effects and effects in populations with prior coronary heart disease. A recent published meta-analysis of observational studies focused on the overall cardiovascular risk associated with NSAIDs, included a variety of individual endpoints such as AMI, stroke, recurrent AMI and all-cause mortality, or the composite of AMI and stroke endpoints. The large number of
included studies and events improved precision of the summary estimates, but studies were very heterogeneous, mostly due to the variety of outcomes and type of included populations.

Our meta-analysis was restricted to acute coronary events occurring in independent populations. A separate publication reported the results of a meta-analysis on the risk of all subtypes of stroke and ischemic stroke associated with the use of individual NSAIDs. The separate evaluation of the risk of AMI and stroke is important before combining coronary and cerebrovascular outcomes. Reliable interpretation of the combined results requires a relatively small gradient of the magnitude of the effect across disease components (i.e. AMI, stroke, death) and of their clinical relevance for individual patients. To separate subtypes of events with different pathophysiology, such hemorrhagic stroke, that can potentially be associated with differential effects with the same individual medication, is of importance.

Figure 4 displays the summary RR for ischemic stroke or AMI obtained from our two separate meta-analyses and also for the combined cardiovascular endpoints reported by McGgettigan and Henry. From our meta-analyses, the direction and magnitude of the summary RR suggest a similar but agent-specific thrombotic effect on the coronary and cerebrovascular system. However, the clinical relevance are expected to be different for each individual patient due to prognostic and quality-of-life differences for stroke and AMI.

The extent of COX-2-dependent prostacyclin inhibition may represent an independent key determinant of the increased thrombotic risk with NSAIDs in the presence of insufficient COX-1 activity (< 95%) to inhibit platelet function. Individual NSAIDs with a degree of COX-2 inhibition less than 90% at therapeutic concentrations (ibuprofen, meloxicam, celecoxib, and etoricoxib) had RR of AMI of 1.18 (95% CI, 1.02–1.38), whereas those with greater COX-2 inhibition (rofecoxib, diclofenac, indometacin, and piroxicam) had RR of 1.60 (95% CI, 1.41–1.81). A similar result was obtained in the evaluation of the occurrence of first AMI in new users of NSAIDs by COX-2 selectivity. However, other mechanisms associated with the use of individual NSAIDs, such as effects mediated through the renal system and increases in arterial blood pressure, could be implicated in the variability of the risk of AMI or stroke across individual NSAIDs.

**Limitations: Role of biases in included studies**

Most of our analyses detected heterogeneity between effect estimates obtained across studies for all the frequently used NSAIDs. We reported random-effects estimates, as recommended in the context of substantial heterogeneity, and for some individual NSAIDs, Tau-squared was still acceptable.

The main limitations of the present meta-analysis descend from the limitations of each of the included studies. Observational studies are prone to confounding, selection, and information bias. Residual confounding can be a major limitation for the majority of the included studies since the magnitude of the increased risks was rather small. Residual confounding might be present in studies that failed to systematically record some life style factors. Few studies adjusted the analysis for socioeconomic status or for education and physical activity. In a separate survey performed on members of one source population, users of COX-2 inhibitors were more likely than nonusers to have lower educational attainment, obesity, and current smoking; investigators estimated that these differences caused a 2% bias away from the null.

Confounding by indication could have operated in opposite directions over the years. The majority of studies accounted for available baseline risk factors for cardiovascular disease. Bias by contraindication to patients with high cardiovascular risk would be minor because only one study included time after the withdrawal of rofecoxib. In this field study, population size did not allow for precise risk estimates for individual NSAIDs. The study reported an increased risk of unstable angina and non-ST-segment elevation MI, but not ST-segment elevation MI, associated with overall NSAID use. The authors hypothesized that...
NSAID-related thrombosis might be less severe than spontaneous thrombosis. Fatal events occurring before hospital arrival were not included. Survival bias might partially explain the results since, on autopsy, most sudden cardiac death victims in the community had a high-grade coronary stenoses, acute coronary lesions, or prior silent MI. Heart failure and atrial fibrillation, events that can be triggered by NSAIDs, are associated with an increased probability of dying from CHD outside the hospital. Lack of ascertainment of such fatalities might have underestimated the risk associated with NSAIDs.

Protopathic bias may occur if exposure to the drug of interest started, stopped, or changed because of an unrecognized manifestation of the disease under study. Indication or protopathic bias was present for the risk of AMI associated with the use of NSAIDs in a small subgroup of patients prescribed NSAIDs for unrecognized preinfarction angina. Protopathic bias can be differential across the individual NSAIDs, especially for those used most frequently for acute pain control.

Inclusion of prevalent NSAID users leads to survival bias and by the inability to control for risk factors that may be modified by NSAIDs. Analysis of new users supported an increased risk of AMI for the most frequently used individual NSAIDs but not for naproxen.

One study was affected by immortal time bias since occurrence of the outcome after the first NSAID prescription was not captured and the unexposed person-time before the start of follow-up of the exposed cohort was not accounted for, which could have underestimated rate ratios comparing the rate of AMI events during current NSAID use with rates during NSAID nonuse.

Hypertension can be considered a causal intermediate factor since it can be an effect of NSAIDs and is an established risk factor for AMI. Thus, adjusting for hypertension or for the use of concurrent antihypertensive medications during follow-up could underestimate RR. Most studies adjusted for hypertension only at baseline; studies that stratified by hypertension status did not observe effect modification. Electronic health databases are limited in assessing changes in blood pressure over time.

Field case–control studies may have been affected by recall or information bias, which results from differential misclassification of exposure between cases and controls. In one study, the time window to recall the exposure was different for cases than for controls, which may have underestimated the RR. Interviews conducted by trained research personnel should be conducted without knowledge of either the disease status or the exposure of interest, but this is very difficult to accomplish. This can result in misclassification bias for either exposure or disease; if different for cases and controls, the misclassification will be differential, and effect estimates may be biased.

Misclassification of exposure may be present since information on the use of over-the-counter (OTC) drugs is not recorded in electronic data. A study assessed use of low-dose aspirin and OTC NSAIDs through a standardized telephone survey and did not find differences in the use of OTC drugs between the individual NSAIDs studied. Based on these published results, although all studies included in the meta-analysis might be affected by misclassification of OTC NSAID use and aspirin use, the bias is likely not differential between individual NSAIDs.

Our subgroup analysis of individual NSAIDs stratified by the concomitant use of aspirin was based on few studies. These very limited results suggested that concomitant use of aspirin might mitigate some, but not all, of the increased risk of AMI associated with diclofenac and likely with rofecoxib. Further evaluation is warranted.

CONCLUSION

Results from observational studies in this meta-analysis confirm variability of effect of individual NSAIDs on the risk of AMI and that almost all of the NSAIDs most frequently used in clinical practice, except naproxen, are associated with an increased risk of AMI at high doses or when used in persons with diagnosed preexisting coronary heart disease. For diclofenac and rofecoxib, this increased risk is present both at low and high doses.

Ongoing large studies, such as the multi-database observational study within the SOS project, might help to elucidate the risk of AMI associated with individual NSAIDs used in different European populations, by dose and duration. Individual studies within this project were performed with similar study design and definitions to minimize heterogeneity across study populations and databases.

ACKNOWLEDGEMENTS

Contributors: NRG and CVL abstracted and compiled the data, FS participated in the development of the literature search strategy, FN developed the database for collection of abstracted data, NRG and BC performed the analyses, CVL drafted the manuscript. CVL, NRG, BC, JC, MS, and SPG facilitated interpretation of the findings. CVL, NRG, JC, MS, and SPG oversaw design of the study and helped draft the manuscript. All

NSAID USE AND RISK OF MYOCARDIAL INFARCTION
coauthors participated in the writing of the manuscript and approved the version submitted for publication.

CVL and the rest of the coauthors had full access to all of the abstracted data from published studies included in this systematic review and take responsibility for the integrity of summarizing the data and the accuracy of the meta-analysis. We would like to thank Ceri Hirst and Miny Samuel for their contributions in planning the literature review and Carla Franzoni for her support in managing the project.

The research leading to the results of this study has received funding from the European Community’s Seventh Framework Programme under grant agreement number 223495 - the SOS project.

KEY POINTS
- Most frequently NSAIDs used in clinical practice, except naproxen, are associated with an increased risk of acute myocardial infarction (AMI) at high doses or in persons with diagnosed coronary heart disease.
- For diclofenac and rofecoxib, the risk was increased at low and high doses
- Ongoing larger studies, performed with a similar study design and definitions, can provide information on the risk of AMI associated with these and other used individual NSAIDs in different European countries with different health systems, according to dose and duration.

CONFLICT OF INTEREST
JC, NRG, CVL, BC, and SPG are employees of RTI-HS. As RTI-HS employees, JC, NRG, and SPG conducted research activities funded by Helsinn Healthcare S.A., and SPG and CVL conducted research activities funded by NicOx S.A, manufacturers of NSAIDs. SPG as RTI-HS employee has served on advisory boards, provided consultation to pharmaceutical companies including NSAID manufacturers/developers such as Helsinn and NicOx S.A, and is a member of the scientific committee of a study on the safety of NSAIDs sponsored by Dundee University. Helsinn and NicOx were not involved in this study. FS and FN have no specific conflict of interest to declare. MS is head of a research unit that occasionally conducts research activities for pharmaceutical companies including Eli Lilly, Pfizer, and AstraZeneca. These research activities are independent of this project.

Preliminary, incomplete results of this meta-analysis were presented at the 26th International Conference of Pharmacoepidemiology and Risk Management, August 19–22, 2010. Brighton, England, UK. (Varas-Lorenzo et al. Pharmacoepidemiol Drug Saf. 2010;19:S142-3)

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article:
- eTable 1. Main characteristics of published studies on the risk of acute myocardial infarction associated with use of individual NSAIDs compared with nonuse or past NSAID use, by geographic area
- eTable 2. Study definitions of low and high dose for individual NSAIDs
- eTable 3. NSAID duration in studies included in meta-analysis
- eTable 4a. Quality assessment according the Newcastle-Ottawa scale: case-control studies
- eTable 4b. Quality assessment according the Newcastle-Ottawa scale: cohort studies
- eTable 5. MOOSE checklist
- eTable 6. Literature search strategy
- eTable 7. Excluded studies, by reason for exclusion
- eFigure 1. Forest plots for cohort and nested case-control studies, ever had an acute myocardial infarction
- eFigure 2. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—naproxen
- eFigure 3. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—ibuprofen
- eFigure 4. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—meloxicam
- eFigure 5. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—diclofenac
- eFigure 6. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—indometacin
- eFigure 7. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—etodolac
- eFigure 8. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—celecoxib
- eFigure 9. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—rofecoxib
REFERENCES

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8. 2 p following 8. DOI:10.1056/NEJM200011213432103.

2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a coloradocolorectal adenoma prevention trial. N Engl J Med 2005; 352: 1092–102. DOI:10.1056/NEJMoa050493.

3. Solomon SD, McMurray JJF, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071–80. DOI:10.1056/NEJMoa050405.

4. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266–74. DOI:10.1111/j.1742-7843.2006.03020.x.

5. Kearney PM, Baigent C, Godwin J, Hall’s H, Emberson JR, Paton J. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302–8. DOI:10.1136/bmj.332.7553.1302.

6. McGeehin P, Henry D. Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase 2. JAMA 2006; 296: 1633–44. DOI:10.1001/jama.296.13.1633.

7. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Eur Heart J 2007; 28: 1296–304. DOI:10.1093/eurheartj/ehm236.

8. Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep 2010; 62: 530–5.

9. Capone ML, Tacconelli S, Scillit MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclo-oxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468–71. DOI:10.1161/01.01.03.003414.

10. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, Ontario: Ottawa Health Research Institute; 2010. Available at: http://www.ohri.utoronto.ca/programashome/clin_epidemiology/oxford.htm. (accessed 9 November 2011).

11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88. DOI:10.1016/0195-6701(86)90046-2.

12. Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 inhibitory selectivity of non-steroidal anti-inflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378–89. DOI:10.1002/art.21887.

13. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Grif

14. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for severe coronary heart disease: Circ Cardiovasc Qual Outcomes 2009; 2: 155–63. DOI:10.1016/j.circoutcomes.2008.10.006.

15. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—etoricoxib eFigure 10. Funnel plot, relative risk of acute myocardial infarction for individual NSAID compared with NSAID nonuse—etoricoxib eList. References for Supplemental Material

Copyright © 2013 John Wiley & Sons, Ltd.
42. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985–90. DOI:10.1016/j.jacc.2003.08.064

43. Adabag AS, Peterson G, Apple FS, Titus J, King R, Luepker RV. Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation. Am Heart J 2010; 159: 33–9. DOI:10.1016/j.ahj.2009.10.019

44. Dudak K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 2011; 123: 46–52. DOI:10.1161/CIRCULATIONAHA.110.964999

45. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873–5.

46. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915–20.

47. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725–32. DOI:10.1038/ncprheum0652.

48. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492–9. DOI:10.1093/aje/kwm324

49. Greenland S. Introduction to regression models. Lippincott-Raven: Hagerstown (MD), 1998.